Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes
Authors:
- Lewis SilvermanLSLewis Silverman
- Mark EllerMEMark Eller
- Linda LintzLLLinda Lintz
- C. L. BeachCBC. L. Beach
- 1 May 2005
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 45 (5) , 597-602
Abstract
The primary objectives of this study were to characterize the absolute bioavailability of azacitidine after subcutaneous (SC) administration and to compare the single‐dose pharmacokinetics of azacitidine following SC and intravenous (IV) administration. Six patients with myelodysplastic syndromes were randomly assigned according to a crossover design to treatment A, consisting of azacitidine administered as a single 75‐mg/m2 SC dose, or treatment B, consisting of azacitidine administered as a single 75‐mg/m2 IV infusion dose over 10 minutes. A minimum of 7 days and a maximum of 28 days were permitted between treatments. The study demonstrated good bioavailability of a SC azacitidine dose compared to an IV infusion treatment. The exposure profiles following SC drug administration illustrate measurable azacitidine levels with bioavailability (AUC) values within 89% of those measured following IV administration (range, 70%‐112%). The median IV half‐life was 0.36 ± 0.02 hours compared to 0.69 ± 0.14 hours for SC administration. Regardless of the route of administration, a single dose of azacitidine, 75 mg/m2, was generally well tolerated.Keywords
This publication has 6 references indexed in Scilit:
- Gene Silencing in Cancer in Association with Promoter HypermethylationNew England Journal of Medicine, 2003
- Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2002
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002
- 5-Azacytidine—A New Anticancer Drug with Significant Activity in Acute Myeloblastic Leukemia1977
- 5-AzacytidineAnnals of Internal Medicine, 1976
- 5-Azacytidine: A New Active Agent for the Treatment of Acute LeukemiaBlood, 1973